Page last updated: 2024-12-11

cinodine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cinodine: glycocinnamoylspermidine antibiotic; gyrase inhibitor found in Nocardia; RN given refers to cpd with unknown MF [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6436146
MeSH IDM0106103

Synonyms (11)

Synonym
ll-bm 123 gamma
antibiotic bm 123gamma
cinodine
antibiotic ll-bm 123 gamma
bm 123 gamma
antibiotic bm 123 gamma
52932-64-6
vxo32pv6q1 ,
unii-vxo32pv6q1
(e)-3-[4-[(2r,3r,4s,5s,6r)-5-[[(2s,3r,4r,5r)-5-[[(3as,6s,7r,7ar)-7-(carbamoylamino)-2-oxo-1,3a,4,6,7,7a-hexahydropyrano[4,3-d][1,3]oxazol-6-yl]oxy]-3-(carbamoylamino)-4-hydroxyoxan-2-yl]carbamoylamino]-3-(diaminomethylideneamino)-4-hydroxy-6-methyloxan-2-
(e)-n-(3-((4-aminobutyl)amino)propyl)-3-(4-(((2r,3r,4s,5s,6r)-3-guanidino-4-hydroxy-5-(3-((2s,3r,4r,5r)-4-hydroxy-5-(((3as,6s,7r,7ar)-2-oxo-7-ureidohexahydro-2h-pyrano[4,3-d]oxazol-6-yl)oxy)-3-ureidotetrahydro-2h-pyran-2-yl)ureido)-6-methyltetrahydro-2h-p

Research Excerpts

Actions

ExcerptReferenceRelevance
"Cinodine was found to inhibit the activity of Micrococcus luteus DNA gyrase in vitro, but it did not inhibit the activities of two other DNA-binding enzymes, namely, topoisomerase I and BamHI."( In vitro inhibition of bacterial DNA gyrase by cinodine, a glycocinnamoylspermidine antibiotic.
Greenstein, M; Maiese, WM; Osburne, MS, 1990
)
1.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (55.56)18.7374
1990's2 (22.22)18.2507
2000's1 (11.11)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]